Nektar Therapeutics (NKTR) Given a $125.00 Price Target by HC Wainwright Analysts

HC Wainwright set a $125.00 target price on Nektar Therapeutics (NASDAQ:NKTR) in a research report sent to investors on Monday morning. The brokerage currently has a buy rating on the biopharmaceutical company’s stock.

NKTR has been the subject of a number of other research reports. BidaskClub cut shares of Nektar Therapeutics from a strong-buy rating to a buy rating in a report on Wednesday, April 18th. Jefferies Group increased their target price on shares of Nektar Therapeutics from $2.12 to $88.00 and gave the stock a buy rating in a report on Tuesday, January 16th. Zacks Investment Research raised shares of Nektar Therapeutics from a sell rating to a hold rating in a report on Wednesday, February 21st. ValuEngine upgraded shares of Nektar Therapeutics from a buy rating to a strong-buy rating in a report on Wednesday, May 2nd. Finally, Cowen reiterated a buy rating and issued a $101.00 price objective on shares of Nektar Therapeutics in a report on Friday, March 2nd. Three equities research analysts have rated the stock with a hold rating, eleven have given a buy rating and one has assigned a strong buy rating to the company’s stock. Nektar Therapeutics has a consensus rating of Buy and an average price target of $79.50.

Nektar Therapeutics opened at $79.23 on Monday, MarketBeat.com reports. The stock has a market capitalization of $14.29 billion, a PE ratio of -144.05 and a beta of 1.79. The company has a debt-to-equity ratio of 4.21, a current ratio of 4.16 and a quick ratio of 4.03. Nektar Therapeutics has a 12 month low of $81.35 and a 12 month high of $83.77.

Nektar Therapeutics (NASDAQ:NKTR) last posted its earnings results on Thursday, May 10th. The biopharmaceutical company reported ($0.60) EPS for the quarter, missing analysts’ consensus estimates of ($0.52) by ($0.08). The company had revenue of $38.02 million during the quarter, compared to the consensus estimate of $35.59 million. Nektar Therapeutics had a negative return on equity of 202.41% and a negative net margin of 40.07%. The firm’s revenue was up 53.7% compared to the same quarter last year. During the same period last year, the company posted ($0.42) EPS. analysts anticipate that Nektar Therapeutics will post 2.58 EPS for the current year.

In other Nektar Therapeutics news, CFO Gil M. Labrucherie sold 90,000 shares of the firm’s stock in a transaction that occurred on Thursday, May 3rd. The shares were sold at an average price of $84.05, for a total transaction of $7,564,500.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Howard W. Robin sold 130,000 shares of the firm’s stock in a transaction that occurred on Thursday, May 3rd. The stock was sold at an average price of $84.05, for a total transaction of $10,926,500.00. Following the transaction, the chief executive officer now owns 280,481 shares of the company’s stock, valued at approximately $23,574,428.05. The disclosure for this sale can be found here. In the last quarter, insiders sold 797,359 shares of company stock valued at $73,089,550. 6.10% of the stock is owned by company insiders.

A number of institutional investors have recently added to or reduced their stakes in the business. Asset Management One Co. Ltd. acquired a new stake in shares of Nektar Therapeutics during the 1st quarter worth approximately $110,000. Daiwa Securities Group Inc. acquired a new stake in shares of Nektar Therapeutics during the 1st quarter worth approximately $111,000. We Are One Seven LLC acquired a new stake in shares of Nektar Therapeutics during the 1st quarter worth approximately $118,000. BB&T Investment Services Inc. acquired a new stake in shares of Nektar Therapeutics during the 4th quarter worth approximately $119,000. Finally, Meeder Asset Management Inc. acquired a new stake in shares of Nektar Therapeutics during the 4th quarter worth approximately $121,000. Hedge funds and other institutional investors own 90.15% of the company’s stock.

About Nektar Therapeutics

Nektar Therapeutics, a research-based biopharmaceutical company, discovers and develops drug candidates for cancer, auto-immune disease, and chronic pain based on its PEGylation and polymer conjugate technology platforms in the United States. The company offers ONZEALD, a topoisomerase I inhibitor that is in Phase III clinical trial for advanced metastatic breast cancer in patients with brain metastases; NKTR-181, an orally-available mu-opioid analgesic molecule, which is in Phase III clinical trial for moderate to severe chronic pain; NKTR-214, a cytokine immunostimulatory therapy that is in Phase I/II to treat cancer; NKTR-358, which is in Phase I to treat autoimmune diseases; and NKTR-262 for solid tumors, as well as NKTR-255 that is under research/preclinical stage for immuno-oncology.

Analyst Recommendations for Nektar Therapeutics (NASDAQ:NKTR)

Receive News & Ratings for Nektar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nektar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit